<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307578</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-G000-409</org_study_id>
    <nct_id>NCT02307578</nct_id>
  </id_info>
  <brief_title>Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332</brief_title>
  <official_title>An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the Extended Access Program (EAP) is to ensure that subjects
      participating in Study E2007-G000-332 continue to have access to perampanel until the time
      perampanel becomes commercially available in the country in which they reside.
    </textblock>
  </brief_summary>
  <overall_status>Temporarily not available</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Seizure Disorder Generalized Tonic Clonic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Perampanel will be available in 2-mg and 4-mg tablets. Subjects will start this EAP with the dose that they were receiving at the end of their participation in Study 332. Doses of perampanel can be adjusted based on clinical judgment.</description>
    <other_name>E2007, Fycompa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Subjects participating in Study E2007-G000-332 (NCT01393743), with at least 52 weeks of
        total exposure to perampanel, and who in the opinion of the treating physician continue to
        benefit from treatment with perampanel.

        Exclusion criteria:

        1. Female subjects who are nursing, pregnant, or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 2, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perampanel</keyword>
  <keyword>Fycompa</keyword>
  <keyword>Primary Generalized Tonic-Clonic Seizures</keyword>
  <keyword>E2007-G000-332</keyword>
  <keyword>E2007</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
